Biology subjects

di Bernardo, D.

Publications and source records attributed to di Bernardo, D..

3 recordsLinked to original sources

bioRxiv2018

A tunable dual-input system for on-demand dynamic geneexpression regulation.

Cellular systems have evolved numerous mechanisms to finely control signalling pathway activation and properly respond to changing environmental stimuli. This is underpinned by dynamic spatiotemporal patterns of gene expression. Indeed, in addition to gene transcription and translation regulation, modulation of protein levels, dynamics and localization are also essential checkpoints that govern cell functions. The introduction of tetracycline-inducible promoters has allowed gene expression control using orthogonal small molecules, facilitating rapid and reversible manipulation to study gene function in biological systems. However, differing protein stabilities means this solely transcriptional regulation is insufficient to allow precise ON-OFF dynamics, thus hindering generation of temporal profiles of protein levels seen in vivo. We developed an improved Tet-On based system augmented with conditional destabilising elements at the post-translational level that permits simultaneous control of gene expression and protein stability. Integrating these properties to control expression of a fluorescent protein in mouse Embryonic Stem Cells (mESCs), we found that adding protein stability control allows faster response times to changes in small molecules, fully tunable and enhanced dynamic range, and vastly improved microfluidic-based in-silico feedback control of gene expression. Finally, we highlight the effectiveness of our dual-input system to finely modulate levels of signalling pathway components in stem cells.

synthetic biology↗

bioRxiv2017

gene2drug: a Computational Tool for Pathway-based Rational Drug Repositioning

MotivationDrug repositioning has been proposed as an effective shortcut to drug discovery. The availability of large collections of transcriptional responses to drugs enables computational approaches to drug repositioning directly based on measured molecular effects.\n\nResultsWe introduce a novel computational methodology for rational drug repositioning, which exploits the transcriptional responses following treatment with small molecule. Specifically, given a therapeutic target gene, a prioritisation of potential effective drugs is obtained by assessing their impact on the transcription of genes in the pathway(s) including the target. We performed in silico validation and comparison with a state-of-art technique based on similar principles. We next performed experimental validation in two different real-case drug repositioning scenarios: (i) upregulation of the glutamate-pyruvate transaminase, which has been shown to induce reduction of oxalate levels in a mouse model of primary hyperoxaluria, and (ii) activation of the transcription factor TFEB, a master regulator of lysosomal biogenesis and autophagy, whose modulation may be beneficial in neurodegenerative disorders.\n\nAvailabilityfree at http://gene2drug.tigem.it\n\nContactdibernardo@tigem.it

bioinformatics↗

bioRxiv2017

Integrated Structure-Transcription analysis of small molecules reveals widespread noise in drug-induced transcriptional responses and a transcriptional signature for drug-induced phospholipidosis

We performed an integrated analysis of drug chemical structures and drug-induced transcriptional responses. We demonstrated that a network representing 3D structural similarities among 5,452 compounds can be used to automatically group together drugs with similar scaffolds and mode-of-action. We then compared the structural network to a network representing transcriptional similarities among a subset of 1,309 drugs for which transcriptional response were available in the Connectivity Map dataset. Analysis of structurally similar, but transcriptionally different, drugs sharing the same mode of action (MOA) enabled us to detect and remove weak and noisy transcriptional responses, greatly enhancing the reliability and usefulness of transcription-based approaches to drug discovery and drug repositioning. Analysis of transcriptionally similar, but structurally different drugs with unrelated MOA, led us to the identification of a \"toxic\" transcriptional signature indicative of lysosomal stress (lysosomotropism) and lipid accumulation (phospholipidosis) partially masking the target-specific transcriptional effects of these drugs. We further demonstrated by High Content Screening that this transcriptional signature is caused by the activation of the transcription factor TFEB, a master regulator of lysosomal biogenesis and autophagy. Our results show that chemical structures and transcriptional profiles provide complementary information and that combined analysis can lead to new insights on on- and off-target effects of small molecules.

bioinformatics↗